ES2895155T3 - Saxitoxinas modificadas en 11,13 para el tratamiento del dolor - Google Patents
Saxitoxinas modificadas en 11,13 para el tratamiento del dolor Download PDFInfo
- Publication number
- ES2895155T3 ES2895155T3 ES16785597T ES16785597T ES2895155T3 ES 2895155 T3 ES2895155 T3 ES 2895155T3 ES 16785597 T ES16785597 T ES 16785597T ES 16785597 T ES16785597 T ES 16785597T ES 2895155 T3 ES2895155 T3 ES 2895155T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- halo
- optionally substituted
- aryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(CN([C@@]1(C)[C@](C(CN(*)*(*)O)N2)NC(NO)=NC)C2=*)C1(C)O Chemical compound CC(CN([C@@]1(C)[C@](C(CN(*)*(*)O)N2)NC(NO)=NC)C2=*)C1(C)O 0.000 description 42
- VTPLNHCFGCPSAR-UHFFFAOYSA-O CC(C(CN1)N2)(NC2=[NH2+])N(C)C1=N Chemical compound CC(C(CN1)N2)(NC2=[NH2+])N(C)C1=N VTPLNHCFGCPSAR-UHFFFAOYSA-O 0.000 description 1
- PHDTZRWSGMEGDZ-CQSPOYSMSA-N CC(CC(N1C[C@@H](C(C(C2(O)O)(N3C)N4C[C@@H]2OC(c2c(C(F)(F)F)ccc(C(F)(F)F)c2)=O)NC3=N)NC4=N)=O)C1=O Chemical compound CC(CC(N1C[C@@H](C(C(C2(O)O)(N3C)N4C[C@@H]2OC(c2c(C(F)(F)F)ccc(C(F)(F)F)c2)=O)NC3=N)NC4=N)=O)C1=O PHDTZRWSGMEGDZ-CQSPOYSMSA-N 0.000 description 1
- HAPDSIPLKFRQLU-UHFFFAOYSA-N CC(CN(C(CO)(C(C(CN(C(CC1)=O)C1=O)N1)N2)NC2=N)C1=N)NC(c1c2OCCc2ccc1)=O Chemical compound CC(CN(C(CO)(C(C(CN(C(CC1)=O)C1=O)N1)N2)NC2=N)C1=N)NC(c1c2OCCc2ccc1)=O HAPDSIPLKFRQLU-UHFFFAOYSA-N 0.000 description 1
- OIYZFQLZUCFDRJ-SEDWIGOZSA-N CC(N[C@@H](CN(C1(C([C@H](CN(C(CC2)=O)C2=O)N2)NC)NC=N)C2=N)[C@H]1O)=O Chemical compound CC(N[C@@H](CN(C1(C([C@H](CN(C(CC2)=O)C2=O)N2)NC)NC=N)C2=N)[C@H]1O)=O OIYZFQLZUCFDRJ-SEDWIGOZSA-N 0.000 description 1
- MVGMZFRPBRUJAQ-UHFFFAOYSA-N CCc1cccc(C(N)=O)c1 Chemical compound CCc1cccc(C(N)=O)c1 MVGMZFRPBRUJAQ-UHFFFAOYSA-N 0.000 description 1
- MJPMFAGDBOWGDE-MLZJXEJWSA-N CN(C(CSC1)=O)/C1=[O]\N(CC(C(C1(O)O)(N2)N3C[C@@H]1OC(c1cc(C(F)(F)F)ccc1C(F)(F)F)=O)NC2=N)C3=N Chemical compound CN(C(CSC1)=O)/C1=[O]\N(CC(C(C1(O)O)(N2)N3C[C@@H]1OC(c1cc(C(F)(F)F)ccc1C(F)(F)F)=O)NC2=N)C3=N MJPMFAGDBOWGDE-MLZJXEJWSA-N 0.000 description 1
- VKPLPDIMEREJJF-UHFFFAOYSA-N COc1cccc(C(N)=O)c1 Chemical compound COc1cccc(C(N)=O)c1 VKPLPDIMEREJJF-UHFFFAOYSA-N 0.000 description 1
- GCVDGLAPBPMPCF-UHFFFAOYSA-N N/C(/c1c(C(F)(F)F)cccc1)=[O]\O[IH](CC1)(C(C(N2)=C(CN(C(CC3)=O)C3=O)N3)(NC2=N)N1C3=N)O Chemical compound N/C(/c1c(C(F)(F)F)cccc1)=[O]\O[IH](CC1)(C(C(N2)=C(CN(C(CC3)=O)C3=O)N3)(NC2=N)N1C3=N)O GCVDGLAPBPMPCF-UHFFFAOYSA-N 0.000 description 1
- DXBQJUMPQKYUJH-BUDIUTNSSA-O N=C(NC(CN(C(CC1)=O)C1=O)C1N2)N(CCC3(O)O)[C@]13NC2=[NH2+] Chemical compound N=C(NC(CN(C(CC1)=O)C1=O)C1N2)N(CCC3(O)O)[C@]13NC2=[NH2+] DXBQJUMPQKYUJH-BUDIUTNSSA-O 0.000 description 1
- UIKVTAQNLSTGEK-GKATWMMFSA-N N=C(NC1C(CN(C(CC2)=O)C2=O)N2)NC1(C([C@H](C1)NC(CCc3cc(C(F)(F)F)ccc3)=O)O)N1C2=N Chemical compound N=C(NC1C(CN(C(CC2)=O)C2=O)N2)NC1(C([C@H](C1)NC(CCc3cc(C(F)(F)F)ccc3)=O)O)N1C2=N UIKVTAQNLSTGEK-GKATWMMFSA-N 0.000 description 1
- ZATPEWPZGBPZMC-DDSVBCIISA-N N=C(NC1[C@H](CN(C(CC2)=O)C2=O)N2)NC1(C(CO)[C@H](C1)OC(NCC(c3ccccc3)c3ccccc3)=O)N1C2=N Chemical compound N=C(NC1[C@H](CN(C(CC2)=O)C2=O)N2)NC1(C(CO)[C@H](C1)OC(NCC(c3ccccc3)c3ccccc3)=O)N1C2=N ZATPEWPZGBPZMC-DDSVBCIISA-N 0.000 description 1
- JXLHSFCJNUDCLK-ZLWAWHNYSA-N N=C(NC1[C@H](CN(C(CC2)=O)C2=O)N2)N[C@@]1(C([C@H](C1)NC(C3(CC3)C(F)(F)F)=O)(O)O)N1C2=N Chemical compound N=C(NC1[C@H](CN(C(CC2)=O)C2=O)N2)N[C@@]1(C([C@H](C1)NC(C3(CC3)C(F)(F)F)=O)(O)O)N1C2=N JXLHSFCJNUDCLK-ZLWAWHNYSA-N 0.000 description 1
- DFKBQZSRDIXJCA-WXFXRELQSA-N N=C(NC1[C@H](CN(C(CC2)=O)C2=O)N2)N[C@@]1([C@@](C(C1)NC(c3cccc(C(F)(F)F)c3)=O)(C=O)O)N1C2=N Chemical compound N=C(NC1[C@H](CN(C(CC2)=O)C2=O)N2)N[C@@]1([C@@](C(C1)NC(c3cccc(C(F)(F)F)c3)=O)(C=O)O)N1C2=N DFKBQZSRDIXJCA-WXFXRELQSA-N 0.000 description 1
- SPCKTUAGGFSMCU-MIPJLZMMSA-N N=C(N[C@H]1C(CN(C(CS2)=O)C2=O)N2)NC1(C([C@H](C1)OC(c3c(C(F)(F)F)ccc(C(F)(F)F)c3)=O)(O)O)N1C2=N Chemical compound N=C(N[C@H]1C(CN(C(CS2)=O)C2=O)N2)NC1(C([C@H](C1)OC(c3c(C(F)(F)F)ccc(C(F)(F)F)c3)=O)(O)O)N1C2=N SPCKTUAGGFSMCU-MIPJLZMMSA-N 0.000 description 1
- VDTLXNYEVYMEOM-LRLVSMCWSA-N N=C1N(C[C@@H](C2O)OC(NC(c3ccccc3)c3ccccc3)=O)C22NCNC2C(CN(C(CC2)=O)C2=O)N1 Chemical compound N=C1N(C[C@@H](C2O)OC(NC(c3ccccc3)c3ccccc3)=O)C22NCNC2C(CN(C(CC2)=O)C2=O)N1 VDTLXNYEVYMEOM-LRLVSMCWSA-N 0.000 description 1
- GRNXTUOKSPKJPC-UHFFFAOYSA-P [NH3+]C(NC1C(CN(C(CC2)=O)C2=O)N2)NC1(C(CC1)(O)O)N1C2=[NH2+] Chemical compound [NH3+]C(NC1C(CN(C(CC2)=O)C2=O)N2)NC1(C(CC1)(O)O)N1C2=[NH2+] GRNXTUOKSPKJPC-UHFFFAOYSA-P 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235412P | 2015-09-30 | 2015-09-30 | |
| PCT/US2016/055050 WO2017059385A1 (en) | 2015-09-30 | 2016-09-30 | 11,13-modified saxitoxins for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2895155T3 true ES2895155T3 (es) | 2022-02-17 |
Family
ID=57200084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16785597T Active ES2895155T3 (es) | 2015-09-30 | 2016-09-30 | Saxitoxinas modificadas en 11,13 para el tratamiento del dolor |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10112953B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3356370B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018534270A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108473503A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016329201A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3000708A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2895155T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL258471A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017059385A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015157559A2 (en) | 2014-04-09 | 2015-10-15 | Siteone Therapeutics, Inc. | 10',11'-modified saxitoxins for the treatment of pain |
| CN110914276A (zh) | 2017-03-29 | 2020-03-24 | 赛特温治疗公司 | 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 |
| BR112019020111A2 (pt) | 2017-03-29 | 2020-05-05 | Siteone Therapeutics Inc | saxitoxinas 11,13-modificadas para o tratamento de dor |
| WO2020072835A1 (en) * | 2018-10-03 | 2020-04-09 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| SI4069691T1 (sl) | 2019-12-06 | 2025-02-28 | Vertex Pharmaceuticals Incorporated | Substituirani tetrahidrofurani kot modulatorji natrijevih kanalčkov |
| KR20230051252A (ko) * | 2020-08-14 | 2023-04-17 | 사이트원 테라퓨틱스, 인코포레이티드 | 통증의 치료를 위한 nav 1.7의 비수화 케톤 억제제 |
| EP4347031B1 (en) | 2021-06-04 | 2025-10-29 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| WO2022256679A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| US20240285596A1 (en) | 2021-06-04 | 2024-08-29 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| JP2024520648A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としての置換テトラヒドロフラン－２－カルボキサミド |
| CA3221960A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| CN113943243B (zh) * | 2021-10-14 | 2023-08-01 | 南开大学 | 一种用于同时鉴定和定量氨基酸的氟探针的制备与应用 |
| EP4511114A1 (en) | 2022-04-22 | 2025-02-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CR20240513A (es) | 2022-04-22 | 2025-04-30 | Vertex Pharma | Compuestos de heteroarilo para el tratamiento del dolor |
| CN119487003A (zh) | 2022-04-22 | 2025-02-18 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| EP4630405A1 (en) | 2022-12-06 | 2025-10-15 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3957996A (en) | 1971-12-08 | 1976-05-18 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic compositions |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| ATE268591T1 (de) | 1995-06-27 | 2004-06-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| DE69719367T2 (de) | 1996-12-20 | 2003-10-16 | Takeda Chemical Industries, Ltd. | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
| EP0857972A1 (en) | 1997-01-24 | 1998-08-12 | Tepual, S.A. | Immunoassay for the detection and quantitation of toxins causing paralytic shellfish poisoning |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| CN1081034C (zh) | 1997-03-07 | 2002-03-20 | 潘心富 | 一种双胍基氢化嘌呤环类化合物的戒毒药 |
| WO1998043619A2 (en) | 1997-04-02 | 1998-10-08 | The Regents Of The University Of California | Method of local anesthesia |
| AU7389098A (en) | 1997-05-16 | 1998-12-08 | Brigham And Women's Hospital | Local anesthetic formulations |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CN1382443A (zh) | 2001-04-25 | 2002-12-04 | 威克斯医疗仪器有限公司 | 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用 |
| JP2003012699A (ja) | 2001-07-04 | 2003-01-15 | Japan Science & Technology Corp | 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品 |
| CN1194693C (zh) | 2002-01-11 | 2005-03-30 | 中国科学院海洋研究所 | 麻痹性贝毒毒素作为制备疗治疼痛病症药物的应用 |
| WO2004050034A2 (en) | 2002-12-02 | 2004-06-17 | Massachusetts Institute Of Technology | Prolonged suppression of electrical activity in excitable tissues |
| AU2003901897A0 (en) | 2003-02-12 | 2003-05-08 | Australian Institute Of Marine Science | Conjugate |
| US20050137177A1 (en) | 2003-12-18 | 2005-06-23 | Shafer Steven L. | Ester combination local anesthetic |
| BRPI0510759A (pt) | 2004-05-07 | 2007-11-20 | Phytotox Ltd | método de facilitar a cura de um ferimento |
| BRPI0510760A (pt) | 2004-05-07 | 2007-11-20 | Phytotox Ltd | método para administrar a um paciente uma composição, composição tópica, e, emplastro |
| RU2277097C1 (ru) | 2004-12-27 | 2006-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Высокомеченный тритием дигидрохлорид [3h]сакситоксина |
| CN101513408A (zh) | 2008-02-19 | 2009-08-26 | 熊平 | 双胍基嘌呤环类衍生物制备提高抗癌药药效的新应用 |
| US8816095B2 (en) | 2008-08-15 | 2014-08-26 | Georgetown University | Na channels, disease, and related assays and compositions |
| CA2760946C (en) * | 2009-05-07 | 2019-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
| CN102811722A (zh) * | 2010-02-10 | 2012-12-05 | 菲特托克斯有限公司 | 用石房蛤毒素衍生物对触觉丧失进行的治疗 |
| ES2786298T3 (es) * | 2011-03-03 | 2020-10-09 | Zalicus Pharmaceuticals Ltd | Inhibidores de benzimidazol del canal de sodio |
| WO2015157559A2 (en) | 2014-04-09 | 2015-10-15 | Siteone Therapeutics, Inc. | 10',11'-modified saxitoxins for the treatment of pain |
-
2016
- 2016-09-30 JP JP2018517286A patent/JP2018534270A/ja not_active Withdrawn
- 2016-09-30 EP EP16785597.2A patent/EP3356370B1/en active Active
- 2016-09-30 US US15/283,187 patent/US10112953B2/en active Active
- 2016-09-30 CN CN201680068998.6A patent/CN108473503A/zh active Pending
- 2016-09-30 ES ES16785597T patent/ES2895155T3/es active Active
- 2016-09-30 AU AU2016329201A patent/AU2016329201A1/en not_active Abandoned
- 2016-09-30 WO PCT/US2016/055050 patent/WO2017059385A1/en not_active Ceased
- 2016-09-30 CA CA3000708A patent/CA3000708A1/en not_active Abandoned
-
2018
- 2018-03-29 IL IL258471A patent/IL258471A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10112953B2 (en) | 2018-10-30 |
| AU2016329201A8 (en) | 2018-05-17 |
| AU2016329201A1 (en) | 2018-04-26 |
| CN108473503A (zh) | 2018-08-31 |
| EP3356370A1 (en) | 2018-08-08 |
| CA3000708A1 (en) | 2017-04-06 |
| WO2017059385A8 (en) | 2017-11-02 |
| WO2017059385A1 (en) | 2017-04-06 |
| EP3356370B1 (en) | 2021-08-18 |
| US20170233398A1 (en) | 2017-08-17 |
| IL258471A (en) | 2018-05-31 |
| JP2018534270A (ja) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2895155T3 (es) | Saxitoxinas modificadas en 11,13 para el tratamiento del dolor | |
| EP3860714B1 (en) | 11,13-modified saxitoxins for the treatment of pain | |
| EP4196482B1 (en) | Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain | |
| US11834456B2 (en) | 11,13-modified saxitoxins for the treatment of pain | |
| US11279706B2 (en) | 11,13-modified saxitoxins for the treatment of pain | |
| US10106549B2 (en) | 10′,11′-modified saxitoxins useful for the treatment of pain |